Mirko Minini
- NAnomédecine, Biologie extracellulaire, Intégratome et Innovations (NABI (UMR 8175 / U1334))
- Centre de Recherche Saint-Antoine (CRSA)
- Institut National de la Santé et de la Recherche Médicale (INSERM)
- Department of Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy
- Department of Surgery “P. Valdoni”, University of Rome “Sapienza”, Rome, Italy.
Présentation
As a cancer scientist, I’m passionate about understanding the intricate crosstalk among CAFs, ECM, and immune cells, as a driver of therapy resistance.
By using cutting-edge approaches and developing advanced animal-free models, I aim to uncover the complexities of tumor biology.
My work is fueled by curiosity, a drive for impactful discoveries, and a belief that collaboration is the key to unlocking breakthroughs in science
Domaines de recherche
Compétences
Publications
Publications
|
|
39P Analysis of the immune response patterns in localized prostate cancerESMO - Immuno-Oncology and Technology, Dec 2024, Geneve, Suisse, Switzerland. pp.100921, ⟨10.1016/j.iotech.2024.100921⟩ |
Deciphering the direct and indirect antitumoral effects of cold atmospheric plasma - application to the cholangiocarcinomaInternational Workshop on Plasma Cancer (IWPCT 8), Mar 2023, Raleigh, United States |
|
Unravelling the multifaceted antitumor effects of cold atmospheric pasma on cholangiocarcinoma2nd annual meeting of COST PlasTher, Sep 2023, Bologna, Italy |
Experimental Model of Biliary Tract Cancers: Subcutaneous Xenograft of Human Cell Lines in Immunodeficient Nude MiceLiver Carcinogenesis, 2769, Springer US, pp.87-98, 2024, Methods in Molecular Biology, ⟨10.1007/978-1-0716-3694-7_7⟩ |
|
Revisiting the Concept of Human DiseaseApproaching Complex Diseases, 2, Springer International Publishing, pp.1-34, 2020, Human Perspectives in Health Sciences and Technology, ⟨10.1007/978-3-030-32857-3_1⟩ |
|
|
ZEB1 regulates BCL2 in cancer-associated fibroblasts to promote cholangiocarcinoma chemoresistance to gemcitabine and cisplatin2025 |